ФАДКЕ Дипак (US),ВОЛФГАНГ Керт Д. (US),ПОЛИМЕРОПОУЛОС Михаэл Х. (US),ФИНИ Джон Джозеф (US),БИРЗНИКС Гунтер (US)
申请号：
RU2014141112
公开号：
RU2014141112A
申请日:
2013.03.14
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating a patient suffering from a mental disorder, which comprises administering to the patient an effective amount of R-P88 or a pharmaceutically acceptable salt or ester of R-P88 or a pharmaceutically acceptable salt of such an ester once a day. The method of claim 1, wherein the disorder is one of the disorders that can be treated with iloperidone. The method of claim 1, wherein the disorder is one of the following disorders: schizophrenia, schizoaffective disorder, bipolar disorder (mania and / or depression), depression, major depression, psychotic episodes, autism, autism spectrum disorders, fragile X-chromosome syndrome and pervasive developmental disorder. 4. The method according to PP. 1, 2 or 3, where R-P88 or a pharmaceutically acceptable salt or ester thereof R-P88 or a pharmaceutically acceptable salt of such an ester is administered orally in a dose of 1 to 24 mg once a day. 5. The method according to PP. 1, 2 or 3, where R-P88 or a pharmaceutically acceptable salt or ester thereof R-P88 or a pharmaceutically acceptable salt of such an ester is administered orally in a dose of 12 to 24 mg once daily. The method according to PP. 1, 2 or 3, which includes administering to the patient an effective amount of R-P88 or a pharmaceutically acceptable salt or ester of R-P88 or a pharmaceutically acceptable salt of such an ester once daily, when titrated to a final dose according to the following schemes: 1 mg one once a day, 2 mg once a day, 4 mg once a day, 6 mg once a day, 8 mg once a day, 10 mg once a day, 12 mg once a day, until the maximum dose is reached 12 mg / day, or 2 mg once a day, 4 mg once a day, 8 mg once a day, 12 mg once a day, 16 mg odi n once a day, 20 mg once a day, 24 mg once a second1. Способ лечения пациента, страдающего от психического расстройства, который заключается во введении пациенту эффективного количества R-P88 или его фармацевтически приемлемой соли или сложного эфира R-P88 или фармацевтически приемлемой соли так
